ProQR Therapeutics (PRQR) Liabilities and Shareholders Equity (2013 - 2025)
ProQR Therapeutics recorded quarterly Liabilities and Shareholders Equity of $131.3 million in Q4 2025, down 26.87% quarter-over-quarter from $179.5 million in Q4 2024, and down 26.87% year-over-year from $179.5 million in Q4 2024.
ProQR Therapeutics' Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $131.3 million for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 26.87% year-over-year to $131.3 million; the TTM figure through Dec 2025 stood at $131.3 million (down 26.87% YoY), while the FY2025 annual figure was $131.3 million, down 26.87% from the prior year.
- Liabilities and Shareholders Equity came in at $131.3 million for Q4 2025 at ProQR Therapeutics, down from $179.5 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $110.5 billion in Q1 2021 to a low of $122.7 million in Q3 2022.
- A 5-year average of $8.1 billion and a median of $177.1 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity soared 96487.99% in 2021 and tumbled 99.81% in 2022, its largest moves.
- ProQR Therapeutics' Liabilities and Shareholders Equity stood at $239.8 million in 2021, then fell by 27.1% to $174.8 million in 2022, then fell by 15.12% to $148.4 million in 2023, then gained by 20.98% to $179.5 million in 2024, then fell by 26.87% to $131.3 million in 2025.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $131.3 million, $179.5 million, and $148.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | 131.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 131.25 Mn |
| Dec 31, 2024 | 179.48 Mn |
| Dec 31, 2023 | 148.35 Mn |
| Sep 30, 2023 | 154.62 Mn |
| Jun 30, 2023 | 161.15 Mn |
| Mar 31, 2023 | 169.60 Mn |
| Dec 31, 2022 | 174.79 Mn |
| Sep 30, 2022 | 122.74 Mn |
| Jun 30, 2022 | 191.06 Mn |
| Mar 31, 2022 | 213.51 Mn |
| Dec 31, 2021 | 239.75 Mn |
| Sep 30, 2021 | 230.35 Mn |
| Jun 30, 2021 | 195.52 Mn |
| Mar 31, 2021 | 110.50 Bn |
| Dec 31, 2020 | 117.71 Mn |
| Sep 30, 2020 | 128.71 Mn |
| Jun 30, 2020 | 102.99 Mn |
| Mar 31, 2020 | 114.41 Mn |
| Dec 31, 2019 | 130.10 Mn |
| Sep 30, 2019 | 90.20 Mn |
| Jun 30, 2019 | 101.41 Mn |
| Mar 31, 2019 | 115,507.63 Bn |
| Dec 31, 2018 | 125.82 Mn |
| Sep 30, 2018 | 138,401.90 Bn |
| Jun 30, 2018 | 44.80 Mn |
| Mar 31, 2018 | 51.93 Bn |
| Dec 31, 2017 | 62.53 Mn |
| Dec 31, 2016 | 70.77 Mn |
| Sep 30, 2016 | 81.28 Bn |
| Dec 31, 2015 | 109.73 Bn |
| Mar 31, 2015 | 132.85 Mn |
| Dec 31, 2014 | 144.04 Mn |
| Sep 30, 2014 | 154.80 Mn |
| Dec 31, 2013 | 6.13 Mn |